In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

280 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-03

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection. The immune response during the acute phase of the infection and after recovery will be compared to the immune response of asymptomatic Spn carriers as well as to the immune response of patients diagnosed with a viral respiratory infection (flu or respiratory syncytial virus (RSV)).

The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with bacterial/viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.

Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until discharge from the hospital or resolution of symptoms. During those visits, questions regarding symptoms will be asked.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts

NCT07295535

Immuno-modulation Immuno-suppression Immunocompromised Patients +2 more

RECRUITING

Understanding COVID-19

NCT04329546

SARS-CoV-2 Viral Kinetics and Host Immune Responses

COMPLETED

Outcomes in Hospitalized Older Patients With COVID-19

NCT04385212

Coronavirus Infection Sars-CoV2 Elderly Infection +1 more

COMPLETED

Acute Upper Respiratory Tract Infection - When is Bacteria Involved?

NCT01580137

Acute Upper Respiratory Tract Infection and Acute Bacterial Rhinosinusitis

UNKNOWN

A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness

NCT05661604

Acute Respiratory Viral Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Infections Respiratory Syncytial Virus (RSV) Infection Influenza Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spn patients

Patients hospitalized with community-acquired pneumonia due to a Streptococcus pneumoniae infection

No interventions assigned to this group

Flu/RSV patients

Patients hospitalized with flu-like symptoms and a laboratory-confirmed influenza or RSV infection

No interventions assigned to this group

Asymptomatic Spn carriers

Healthy people screened for asymptomatic carriage of Streptococcus pneumoniae

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 60-85 years
* Able to provide informed consent either independently or by a legal representative
* Group 1 (Spn pneumonia patients): clinical and/or radiological signs of pneumonia
* Group 1 (Spn pneumonia patients): positive Spn urinary antigen and/or blood culture and/or positive sputum test.
* Group 2 (viral respiratory infection patients): clinical signs of a respiratory infection
* Group 2 (viral respiratory infection patients): positive test for influenza or RSV
* Group 3 (asymptomatic Spn-carriers): healthy without clinical signs of infection and no lower respiratory symptoms within the last month.

Exclusion Criteria

* Immunosuppression,
* Use of inhalation and/or nasal steroids the last month
* Intubation or under invasive mechanical ventilation
* Long-term antibiotic treatment prior to disease onset

Minimum Eligible Age

60 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes